Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scopolamine - Repurposed Therapeutics

Next Previous
Drug Profile

Scopolamine - Repurposed Therapeutics

Alternative Names: DPI-385-CVS; DPI-386; DPI-386 Nasal Gel; DPI-386-SG; DPI-386-SS; DPI-387; DPI-521-CG; DPI-550-TBI; INSCOP spray; Scopolamine HBr - Repurposed Therapeutics

Latest Information Update: 06 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epiomed Therapeutics
  • Developer National Aeronautics and Space Administration; Repurposed Therapeutics
  • Class Antidepressants; Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Small molecules; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Motion sickness
  • Phase II Familial cyclic vomiting syndrome
  • Phase I Bipolar depression; Chemically-induced disorders; Depressive disorders; Major depressive disorder
  • Preclinical Traumatic brain injuries; Unspecified

Most Recent Events

  • 30 Jan 2024 Defender Pharmaceuticals intends to schedule a formal meeting with the US FDA to fully understand the issues raised in the Complete Response Letter (CRL), as well as develop and implement a comprehensive action plan
  • 30 Jan 2024 Defender Pharmaceuticals receives complete response letter from the US FDA for Motion sickness (Prevention, In adults) (Intranasal)
  • 26 Sep 2023 Defender plans for Launh of scopolamine for Motion sickness (Prevention) in USA (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top